{"groups":[{"description":"Cabazitaxel 20 mg/m\\^2 intravenous (IV) infusion over 1 hour on Day 1 of each 21-day cycle in combination with Prednisone (or Prednisolone) 10 mg orally daily until disease progression (DP), unacceptable toxicity, participant's refusal of further study treatment or for a maximum of 10 cycles.","id":"FG000","title":"Cabazitaxel 20 mg/m^2"},{"description":"Cabazitaxel 25 mg/m\\^2 IV infusion over 1 hour on Day 1 of each 21-day cycle in combination with Prednisone (or Prednisolone) 10 mg orally daily until DP, unacceptable toxicity, participant's refusal of further study treatment or for a maximum of 10 cycles.","id":"FG001","title":"Cabazitaxel 25 mg/m^2"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"7"}],"type":"Lost to Follow-up"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"598"},{"groupId":"FG001","numSubjects":"602"}],"type":"STARTED"},{"achievements":[{"comment":"Random assignment, was not actual treatment in some cases","groupId":"FG000","numSubjects":"587"},{"comment":"Random assignment, was not actual treatment in some cases","groupId":"FG001","numSubjects":"588"}],"type":"Treated"},{"achievements":[{"comment":"Completed participants included those who withdrew treatment consent but were followed for survival","groupId":"FG000","numSubjects":"586"},{"comment":"Completed participants included those who withdrew treatment consent but were followed for survival","groupId":"FG001","numSubjects":"595"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"7"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Participants were randomized by Interactive Voice Response System (IVRS) in 1:1 ratio (Cabazitaxel 20 mg/m\\^2: Cabazitaxel 25 mg/m\\^2) and stratified according to Eastern Cooperative Oncology Group Performance Status (ECOG PS) score (0 or 1 versus 2), measurability of disease (measurable versus non-measurable) and region.","recruitmentDetails":"The study was conducted at 172 centers in 22 countries. A total of 1463 participants were screened between 19 April 2011 and 18 November 2013. Out of 1463 participants, 1200 participants were enrolled in this study and 263 were not eligible to join the study."}